An

Authors :: Haneen, Sadick
Elena, Schäfer
Christel, Weiss
Nicole, Rotter
Cornelia Emika, Müller
Richard, Birk
Maliha, Sadick
Daniel, Häussler
Source :: Experimental and therapeutic medicine. 24(3)
Publication Year :: 2022
Abstract: Previous studies have demonstrated that vascular endothelial growth factor (VEGF) is upregulated in patients with hereditary hemorrhagic telangiectasia (HHT). The use of Bevacizumab as an anti-angiogenic treatment agent seems promising. The purpose of the present

Tools